Shares in Circassia fall on forecast sales miss and potential funding dilemma
Investors are spooked by pharmaceutical firm Circassia Pharmaceuticals' (CIR) warning that it may need third party funding to acquire the full US commercial rights to flagship drug Tudorza.Sales are also expected to fall to a range...
04 January 2019
